Are corticosteroids used as first-line treatment for acute autoimmune hepatitis?

Yes, corticosteroids are the cornerstone first-line treatment for acute autoimmune hepatitis and should be initiated in most patients.

Corticosteroids, specifically prednisolone at 0.5 mg/kg/day (up to 1 mg/kg/day in severe disease), combined with azathioprine, represent the standard first-line therapy for autoimmune hepatitis. 1, 2

Treatment Algorithm

Initial Therapy Selection

Standard approach (most patients):

• Start prednisolone 0.5 mg/kg/day (maximum 40 mg/day) as single morning dose
• Add azathioprine after 2 weeks if bilirubin <6 mg/dl
• Initial azathioprine dose: 50 mg/day, increase to 1-2 mg/kg/day over 2-4 weeks 1, 2

Higher dose steroids (severe/advanced disease):

• Prednisolone up to 1 mg/kg/day may be used in more severe presentations
• Meta-analysis shows higher doses achieve better biochemical response but with more adverse effects 1

Special Circumstances Requiring Steroid Monotherapy

Use prednisolone alone (without azathioprine) in these specific situations 2:

1. Decompensated cirrhosis - avoid steroid-sparing agents initially
2. Uncertain AIH diagnosis - steroids alone help confirm diagnosis through response
3. Expected short treatment duration - when drug precipitant identified and withdrawn
4. TPMT homozygous deficiency - substitute mycophenolate mofetil instead
5. Current/recent malignancy - reluctance to use immunosuppressants

Alternative Steroid: Budesonide

Budesonide 9 mg/day can be considered in adults WITHOUT cirrhosis if major concern exists about cosmetic steroid side effects 2:

• Similar biochemical response rates to prednisolone
• Lower cosmetic adverse effects (weight gain, cushingoid features)
• Contraindicated in cirrhosis due to reduced first-pass metabolism
• Not recommended as first-line in children

Critical Tapering Considerations

Slow corticosteroid tapering is superior to rapid tapering in acute presentations 3:

• In acute icteric AIH: slow tapering achieved 99% vs 71% adverse outcome-free survival (P<0.0001)
• In acute-severe AIH: slow tapering achieved 92% vs 54% adverse outcome-free survival (P<0.001)
• Slow tapering defined as: taking ≥3 weeks to reduce prednisone below 20 mg/day
• Rapid tapering independently predicted more adverse events (OR 0.144)

Standard tapering approach 1, 2:

• Reduce prednisolone gradually over 1-3 months to 5-10 mg/day
• Taper guided by ALT and IgG response
• Monitor at weeks 4,12, and 24 initially
• As steroids decrease, increase azathioprine from 1 to 2 mg/kg/day

Monitoring Requirements

Essential baseline assessments before starting steroids 1, 2:

• TPMT enzyme activity (before azathioprine)
• Hepatitis B status (surface antigen and core antibody)
• Bone density (DEXA scan) for fracture risk
• Intraocular pressure (baseline ophthalmology)
• Pregnancy test in women of childbearing age

During treatment 1, 2:

• ALT and IgG at 4,12, and 24 weeks
• Complete blood count (especially first 6 weeks with azathioprine)
• Every 2-3 months until biochemical response achieved
• Then every 3-6 months during maintenance

Common Pitfalls to Avoid

1. Don't delay azathioprine addition beyond 2 weeks (unless bilirubin >6 mg/dl) - combination therapy reduces steroid exposure and improves outcomes 2

2. Don't use budesonide in cirrhotic patients - intrahepatic shunting reduces efficacy and increases systemic exposure 2

3. Don't taper steroids too rapidly in acute presentations - slow tapering significantly reduces adverse outcomes 3

4. Don't withhold treatment in mild AIH without careful consideration - even asymptomatic patients generally benefit from treatment, though mild disease (ALT <50, minimal inflammation/fibrosis) requires individualized risk-benefit assessment 2

5. Avoid methylprednisolone IV - hepatotoxicity reported in 6-8% of patients, with 2% severe cases 2

Steroid-Related Side Effect Management

Proactive management is essential 1:

• Vitamin D supplementation and calcium optimization
• FRAX score calculation for fracture risk
• Consider bisphosphonates in high-risk patients
• Regular ophthalmology follow-up (intraocular pressure monitoring)
• Monitor for metabolic complications (diabetes, hypertension, weight gain)

Up to 70% of patients report side effects and reduced quality of life during corticosteroid therapy, making steroid-sparing strategies with azathioprine or mycophenolate mofetil critical 1.